RTTNews BiotechCodex · 实盘不做把握 5/10
北京时间·🕒 发布 15:35:18时区推断·⟳ 抓取 15:45:21·⚡ 决策 07-15 15:52:42 +7m21s·104.4 天前
Biogen和卫材公布LEQEMBI真实世界研究中83%早期阿尔茨海默患者稳定或改善
LEADER研究为真实世界中期数据，支持LEQEMBI临床叙事，但不是新适应症批准、指南纳入或销售指引上修。
📄 原文RTTNews Biotech↗ 原文
Biogen Inc. (BIIB) and Eisai Co., Ltd. announced results from the real-world LEADER study presented at AAIC 2026, showi…
不做 Biogen（BIIB.US）
不做：会议真实世界数据偏叙事支持，不是新批准或销售上修；且消息已发布约两天并伴随股价下跌。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-13 · 扩散 medium · price-in 风险 medium ↗
关键理由
- LEADER研究为真实世界中期数据，支持LEQEMBI临床叙事，但不是新适应症批准、指南纳入或销售指引上修。
主要风险
- LEQEMBI商业化仍受输注便利性、安全监测和支付覆盖制约，单项会议数据难以直接转化为短线销售增量。
原文全文
展开原文 · 2,131 字
Biogen Inc. (BIIB) and Eisai Co., Ltd. announced results from the real-world LEADER study presented at AAIC 2026, showing that nearly 83% of early Alzheimer's disease patients treated with LEQEMBI remained stable (75.9%) or improved (6.6%) over an average of 17 months of therapy.
Alzheimer's disease is a chronic, progressive condition that requires continuous treatment. LEQEMBI, an antibody targeting amyloid beta, works by removing both insoluble plaque and soluble protofibrils, aiming to slow cognitive decline and preserve daily functioning. Data suggested that ongoing treatment may help patients remain in the early stages of disease longer, which includes mild cognitive impairment due to Alzheimer's and mild Alzheimer's dementia.
The LEADER study is a three-year, multicenter, retrospective analysis conducted across 13 U.S. sites. It integrates deidentified patient charts, electronic medical records and healthcare provider surveys to assess treatment persistence, safety, and functional outcomes in diverse clinical settings.
The interim analysis included 432 patients with a mean age of 74, of whom 55.8% were female. At baseline, 63.9% had mild cognitive impairment due to Alzheimer's, while 36.1% had mild Alzheimer's dementia.
Patients received an average of 26 LEQEMBI infusions over 520 days of treatment. Stability was defined as remaining in the same disease stage, while improvement was marked by a transition from mild dementia back to mild cognitive impairment. Progression was defined as advancing to moderate dementia.
BIIB has traded between $121.05 and $219.72 over the past year. The stock closed Tuesday's trading at $191.95, down 8.17%.
For comments and feedback contact: editorial@rttnews.com
Business News
July 13, 2026 10:12 ET The week saw the release of the minutes of the Federal Reserve’s latest monetary policy session, foreign trade figures and survey data on manufacturing and services in the U.S. External trade data from Germany was the highlight in Europe, while the latest macroeconomic projections from the Asian Development Bank and the International Monetary Fund gained attention.
Alzheimer's disease is a chronic, progressive condition that requires continuous treatment. LEQEMBI, an antibody targeting amyloid beta, works by removing both insoluble plaque and soluble protofibrils, aiming to slow cognitive decline and preserve daily functioning. Data suggested that ongoing treatment may help patients remain in the early stages of disease longer, which includes mild cognitive impairment due to Alzheimer's and mild Alzheimer's dementia.
The LEADER study is a three-year, multicenter, retrospective analysis conducted across 13 U.S. sites. It integrates deidentified patient charts, electronic medical records and healthcare provider surveys to assess treatment persistence, safety, and functional outcomes in diverse clinical settings.
The interim analysis included 432 patients with a mean age of 74, of whom 55.8% were female. At baseline, 63.9% had mild cognitive impairment due to Alzheimer's, while 36.1% had mild Alzheimer's dementia.
Patients received an average of 26 LEQEMBI infusions over 520 days of treatment. Stability was defined as remaining in the same disease stage, while improvement was marked by a transition from mild dementia back to mild cognitive impairment. Progression was defined as advancing to moderate dementia.
BIIB has traded between $121.05 and $219.72 over the past year. The stock closed Tuesday's trading at $191.95, down 8.17%.
For comments and feedback contact: editorial@rttnews.com
Business News
July 13, 2026 10:12 ET The week saw the release of the minutes of the Federal Reserve’s latest monetary policy session, foreign trade figures and survey data on manufacturing and services in the U.S. External trade data from Germany was the highlight in Europe, while the latest macroeconomic projections from the Asian Development Bank and the International Monetary Fund gained attention.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。